I-Mab [IMAB]

Source: 

Company Overview

I-mab is a U.S.-based global biotech company exclusively focused on the development and potential commercialization of highly differentiated immunotherapies for the treatment of cancer. Following the divestiture of the Greater China assets and business operations and as of the date of this annual report, we have developed an innovative pipeline of three clinical stage assets through our internal research and development efforts and collaboration arrangements with global pharmaceutical and biotech companies.